about
Biosimilars in rheumatology: understanding the rigor of their developmentReview: basics of drug development in rheumatologyConsistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab).Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in GastroenterologyBiosimilars: what do patients need to consider?Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.Biosimilars: how similar?Certolizumab pegol in axial spondyloarthritis.Drift, evolution, and divergence in biologics and biosimilars manufacturing.Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices.Biosimilars: clinical interpretation and implications for drug development.Biosimilars in rheumatology: current perspectives and lessons learnt.Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.Biosimilars for psoriasis: preclinical analytical assessment to determine similarity.Current Status of Biosimilars in Oncology.Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.Biosimilars for psoriasis: clinical studies to determine similarity.Interchangeability of Biosimilars: A European Perspective.Update on biosimilars in rheumatology.Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.The structure-function relationship of disulfide bonds in etanercept.Is a Biologic Produced 15 Years Ago a Biosimilar of Itself Today?Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?Position of the Canadian Association of Gastroenterology on subsequent entry biologics is challenged by biosimilar industry representatives.Maintaining consistent quality and clinical performance of biopharmaceuticals.Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.Manufacturing history of etanercept (Enbrel®): Consistency of product quality through major process revisions.The process defines the product: what really matters in biosimilar design and production?Biosimilar monoclonal antibodies (mAbs) in oncology.Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab.A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.Totality of the evidence at work: The first U.S. biosimilar.Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland.
P2860
Q26744773-40A31050-5AD3-4CFF-A8AA-FD032D71B82BQ28083593-F3282CEF-B46A-47D2-A053-77FACEA9FC5EQ30377369-70B6DAA6-CBBF-4A36-A4FF-39F12E8D4E0DQ33636715-771BFE5A-9891-4E29-A4B3-F7B6BF596A16Q36215828-6AF2AB26-7D09-4ED7-B1E7-93FA4EB234FBQ37704338-4C12BE27-77D8-449A-A94C-B85278CD1600Q38151938-5037A2E5-F2B2-40E0-B54F-C56EB24E3B10Q38161555-2C9242B2-2035-41E5-AB53-DA358008BD23Q38190917-14DC7547-95D2-4E53-8FD1-E4A7C57F4452Q38291910-97B6566A-477F-43D3-A65F-FD5FC4C7B561Q38331244-A5FE5E5B-17BC-4E3E-B520-8D1DF26506DCQ38568463-CF775F81-B61D-4557-ABBC-BC1F47679F44Q38591241-1FA854A1-5CAC-4DA9-AD2F-D466163C3365Q38591272-E1FFA519-F37B-4BC8-9F1F-2E7992A1A6DDQ38592363-56A585A7-FFD8-45BC-BDDF-8059C0668FB1Q38621681-3B063B37-7E32-4C60-8EA4-3E740785E5CFQ38687093-78F6BD29-6587-4D99-8ECE-07D74809A950Q38844794-66A6C63A-A923-48AB-A67C-1C81F499D014Q38910179-8F30856A-162A-4AB9-AF63-441DAD3D14CAQ38937842-C749D340-8AA6-45AB-AB2B-CA79D5F858F9Q38957406-A573935E-BD14-44E5-8FD9-BA56CCA1A9DFQ39000780-EE17A908-6D8E-4DDD-8C58-6DCE402AC171Q39164941-0FB897D2-4C2C-4811-9051-2040ECBFDF50Q39184810-5A1D0D74-753F-404D-BE6E-DA8A74BEEC24Q41073658-A15443F8-1778-4DD9-A0B0-E066947B7B7CQ42056856-7A012EFA-6EFE-47FB-9D6C-56982ECF5BDAQ42360803-B73DD483-9CFF-47A0-8CE8-181B3474C3C9Q42962750-D47D2FAA-7157-4C5A-93A9-C615DE3FA8F8Q47246881-D7FB3679-A344-4040-A55D-621C3C19E563Q47807650-1B1298C8-4EC3-4A6F-9011-C72DD83FC865Q50094418-5C480AB6-325D-4A0C-B103-CC013AAE7029Q50115805-316A50E3-EF09-4E75-88F0-E2FD6D1D2809Q50207250-387F1789-587E-4BD2-8EE0-E806DC20136EQ51022840-3148EC9E-EF4F-4C05-B664-197BB3FB6CE2Q51793470-D7D4589A-3F52-4B47-B596-9A4058692EE8Q53170870-182022C8-8B43-446D-997D-E19CD939F406Q53964916-0F51F4B9-3737-4FA6-806B-F28781EDA0E4Q54959955-2C70FF3B-1F48-4BA2-A21A-0AAF5D08F0F9Q55008089-2D249FD8-CDBD-4836-8E50-535883C1329EQ55248209-9035A991-E3F3-496A-B833-95820D24C0C8
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Biosimilars in rheumatology: the wind of change.
@en
Biosimilars in rheumatology: the wind of change.
@nl
type
label
Biosimilars in rheumatology: the wind of change.
@en
Biosimilars in rheumatology: the wind of change.
@nl
prefLabel
Biosimilars in rheumatology: the wind of change.
@en
Biosimilars in rheumatology: the wind of change.
@nl
P1476
Biosimilars in rheumatology: the wind of change.
@en
P2093
Christian K Schneider
P304
P356
10.1136/ANNRHEUMDIS-2012-202941
P407
P577
2013-03-01T00:00:00Z